BEAM 101
Alternative Names: BEAM-101Latest Information Update: 13 Dec 2024
At a glance
- Originator Beam Therapeutics
- Class Antianaemics; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Sickle cell anaemia
- No development reported Beta-thalassaemia
Most Recent Events
- 11 Dec 2024 Interim efficacy and adverse events data from a phase I/II BEACON trial for Sickle cell disease released by Beam Therapeutics
- 07 Dec 2024 Efficacy data from a phase I/II BEACON trial in Sickle cell anaemia presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
- 07 Dec 2024 Adverse events and efficacy data from a phase I/II BEACON trial in Sickle cell anaemia presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)